Celso S. G. Catumbela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Celso S. G. Catumbela has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Rodrigo Morales
Department of Neurology, The University of Texas Health Science Center at Houston
5 shared publications Bhanu P. Ganesh
Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, USA
2 shared publicationsCarlos Henrique R. Catalão
Faillace Department of Psychiatry and Behavioural Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, USA
2 shared publications- Claudio Soto
The University of Texas Health Science Center at Houston
2 shared publications Fabricia Petronilho
Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Criciúma, Brazil
2 shared publicationsFelipe Dal-Pizzol
Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Criciúma, Brazil
2 shared publications
Latest Publications
- 28 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (14) , e23843
Adaptation of the protein misfolding cyclic amplification (PMCA) technique for the screening of anti‐prion compounds
Prion diseases result from the misfolding of the physiological prion protein (PrP C ) to a pathogenic conformation (PrP Sc ). Compelling evidence indicates that prevention and/or reduction of PrP Sc replication are promising therapeutic strategies against prion diseases. However, the existence of different PrP Sc conformations (or strains) associated with disease represents a major problem when identifying anti‐prion compounds. Efforts to identify strain‐specific anti‐prion molecules are limited by the lack of biologically relevant high‐throughput screening platforms to interrogate compound libraries. Here, we describe adaptations to the protein misfolding cyclic amplification (PMCA) technology (able to faithfully replicate PrP Sc strains) that increase its throughput to facilitate the screening of anti‐prion molecules. The optimized PMCA platform includes a reduction in sample and reagents, as well as incubation/sonication cycles required to efficiently replicate and detect rodent‐adapted and cervid PrP Sc strains. The visualization of PMCA products was performed via dot blots, a method that contributed to reduced processing times. These technical changes allowed us to evaluate small molecules with previously reported anti‐prion activity. This proof‐of‐principle screening was evaluated for six rodent‐adapted prion strains. Our data show that these compounds targeted either none, all or some PrP Sc strains at variable concentrations, demonstrating that this PMCA system is suitable to test compound libraries for putative anti‐prion molecules targeting specific PrP Sc strains. Further analyses of a small compound library against deer prions demonstrate the potential of this new PMCA format to identify strain‐specific anti‐prion molecules. The data presented here demonstrate the use of the PMCA technique in the selection of prion strain‐specific anti‐prion compounds.
- 28 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (14) , e23843
Adaptation of the protein misfolding cyclic amplification (PMCA) technique for the screening of anti‐prion compounds
Prion diseases result from the misfolding of the physiological prion protein (PrP C ) to a pathogenic conformation (PrP Sc ). Compelling evidence indicates that prevention and/or reduction of PrP Sc replication are promising therapeutic strategies against prion diseases. However, the existence of different PrP Sc conformations (or strains) associated with disease represents a major problem when identifying anti‐prion compounds. Efforts to identify strain‐specific anti‐prion molecules are limited by the lack of biologically relevant high‐throughput screening platforms to interrogate compound libraries. Here, we describe adaptations to the protein misfolding cyclic amplification (PMCA) technology (able to faithfully replicate PrP Sc strains) that increase its throughput to facilitate the screening of anti‐prion molecules. The optimized PMCA platform includes a reduction in sample and reagents, as well as incubation/sonication cycles required to efficiently replicate and detect rodent‐adapted and cervid PrP Sc strains. The visualization of PMCA products was performed via dot blots, a method that contributed to reduced processing times. These technical changes allowed us to evaluate small molecules with previously reported anti‐prion activity. This proof‐of‐principle screening was evaluated for six rodent‐adapted prion strains. Our data show that these compounds targeted either none, all or some PrP Sc strains at variable concentrations, demonstrating that this PMCA system is suitable to test compound libraries for putative anti‐prion molecules targeting specific PrP Sc strains. Further analyses of a small compound library against deer prions demonstrate the potential of this new PMCA format to identify strain‐specific anti‐prion molecules. The data presented here demonstrate the use of the PMCA technique in the selection of prion strain‐specific anti‐prion compounds.
- Open Access
- 1 October 2023
- Published by Springer Nature in Molecular Psychiatry
- Vol. 28 (10) , 4487-4488
Correction: Sepsis exacerbates Alzheimer’s disease pathophysiology, modulates the gut microbiome, increases neuroinflammation and amyloid burden
- 1 October 2023
- Published by Springer Nature in Molecular Psychiatry
- Vol. 28 (10) , 4487-4488
Open AccessCorrection: Sepsis exacerbates Alzheimer’s disease pathophysiology, modulates the gut microbiome, increases neuroinflammation and amyloid burden
- 14 July 2023
- Published by Springer Nature in Molecular Psychiatry
- Vol. 28 (10) , 4463-4473
Sepsis exacerbates Alzheimer’s disease pathophysiology, modulates the gut microbiome, increases neuroinflammation and amyloid burden
While our understanding of the molecular biology of Alzheimer’s disease (AD) has grown, the etiology of the disease, especially the involvement of peripheral infection, remains a challenge. In this study, we hypothesize that peripheral infection represents a risk factor for AD pathology. To test our hypothesis, APP/PS1 mice underwent cecal ligation and puncture (CLP) surgery to develop a polymicrobial infection or non-CLP surgery. Mice were euthanized at 3, 30, and 120 days after surgery to evaluate the inflammatory mediators, glial cell markers, amyloid burden, gut microbiome, gut morphology, and short-chain fatty acids (SCFAs) levels. The novel object recognition (NOR) task was performed 30 and 120 days after the surgery, and sepsis accelerated the cognitive decline in APP/PS1 mice at both time points. At 120 days, the insoluble Aβ increased in the sepsis group, and sepsis modulated the cytokines/chemokines, decreasing the cytokines associated with brain homeostasis IL-10 and IL-13 and increasing the eotaxin known to influence cognitive function. At 120 days, we found an increased density of IBA-1-positive microglia in the vicinity of Aβ dense-core plaques, compared with the control group confirming the predictable clustering of reactive glia around dense-core plaques within 15 μm near Aβ deposits in the brain. In the gut, sepsis negatively modulated the α- and β-diversity indices evaluated by 16S rRNA sequencing, decreased the levels of SCFAs, and significantly affected ileum and colon morphology in CLP mice. Our data suggest that sepsis-induced peripheral infection accelerates cognitive decline and AD pathology in the AD mouse model.
- 14 July 2023
- Published by Springer Nature in Molecular Psychiatry
- Vol. 28 (10) , 4463-4473
Sepsis exacerbates Alzheimer’s disease pathophysiology, modulates the gut microbiome, increases neuroinflammation and amyloid burden
While our understanding of the molecular biology of Alzheimer’s disease (AD) has grown, the etiology of the disease, especially the involvement of peripheral infection, remains a challenge. In this study, we hypothesize that peripheral infection represents a risk factor for AD pathology. To test our hypothesis, APP/PS1 mice underwent cecal ligation and puncture (CLP) surgery to develop a polymicrobial infection or non-CLP surgery. Mice were euthanized at 3, 30, and 120 days after surgery to evaluate the inflammatory mediators, glial cell markers, amyloid burden, gut microbiome, gut morphology, and short-chain fatty acids (SCFAs) levels. The novel object recognition (NOR) task was performed 30 and 120 days after the surgery, and sepsis accelerated the cognitive decline in APP/PS1 mice at both time points. At 120 days, the insoluble Aβ increased in the sepsis group, and sepsis modulated the cytokines/chemokines, decreasing the cytokines associated with brain homeostasis IL-10 and IL-13 and increasing the eotaxin known to influence cognitive function. At 120 days, we found an increased density of IBA-1-positive microglia in the vicinity of Aβ dense-core plaques, compared with the control group confirming the predictable clustering of reactive glia around dense-core plaques within 15 μm near Aβ deposits in the brain. In the gut, sepsis negatively modulated the α- and β-diversity indices evaluated by 16S rRNA sequencing, decreased the levels of SCFAs, and significantly affected ileum and colon morphology in CLP mice. Our data suggest that sepsis-induced peripheral infection accelerates cognitive decline and AD pathology in the AD mouse model.
- Open Access
- 18 June 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (6) , 761
Multi-Dose Intravenous Administration of Neutral and Cationic Liposomes in Mice: An Extensive Toxicity Study
Liposomes are widely used as delivery systems for therapeutic purposes. However, the toxicity associated with the multi-dose administration of these nanoparticles is not fully elucidated. Here, we evaluated the toxicity of the prolonged administration of liposomes composed of neutral or cationic phospholipids often used in drug and gene delivery. For that purpose, adult wild-type mice (C57Bl6) were randomly distributed into three groups receiving either vehicle (PBS), neutral, or cationic liposomes and subjected to repeated intravenous injections for a total of 10 doses administered over 3 weeks. Several parameters, including mortality, body weight, and glucose levels, were monitored throughout the trial. While these variables did not change in the group treated with neutral liposomes, the group treated with the positively charged liposomes displayed a mortality rate of 45% after 10 doses of administration. Additional urinalysis, blood tests, and behavioral assays to evaluate impairments of motor functions or lesions in major organs were also performed. The cationic group showed less forelimb peak force than the control group, alterations at the hematological level, and inflammatory components, unlike the neutral group. Overall, the results demonstrate that cationic liposomes are toxic for multi-dose administration, while the neutral liposomes did not induce changes associated with toxicity. Therefore, our results support the use of the well-known neutral liposomes as safe drug shuttles, even when repetitive administrations are needed.
- 18 June 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (6) , 761
Open AccessMulti-Dose Intravenous Administration of Neutral and Cationic Liposomes in Mice: An Extensive Toxicity Study
Liposomes are widely used as delivery systems for therapeutic purposes. However, the toxicity associated with the multi-dose administration of these nanoparticles is not fully elucidated. Here, we evaluated the toxicity of the prolonged administration of liposomes composed of neutral or cationic phospholipids often used in drug and gene delivery. For that purpose, adult wild-type mice (C57Bl6) were randomly distributed into three groups receiving either vehicle (PBS), neutral, or cationic liposomes and subjected to repeated intravenous injections for a total of 10 doses administered over 3 weeks. Several parameters, including mortality, body weight, and glucose levels, were monitored throughout the trial. While these variables did not change in the group treated with neutral liposomes, the group treated with the positively charged liposomes displayed a mortality rate of 45% after 10 doses of administration. Additional urinalysis, blood tests, and behavioral assays to evaluate impairments of motor functions or lesions in major organs were also performed. The cationic group showed less forelimb peak force than the control group, alterations at the hematological level, and inflammatory components, unlike the neutral group. Overall, the results demonstrate that cationic liposomes are toxic for multi-dose administration, while the neutral liposomes did not induce changes associated with toxicity. Therefore, our results support the use of the well-known neutral liposomes as safe drug shuttles, even when repetitive administrations are needed.
- Open Access
- 25 November 2020
- Published by The Royal Society in Open Biology
- Vol. 10 (11) , 200282
Understanding and exploiting interactions between cellular proteostasis pathways and infectious prion proteins for therapeutic benefit
Several neurodegenerative diseases of humans and animals are caused by the misfolded prion protein (PrP Sc ), a self-propagating protein infectious agent that aggregates into oligomeric, fibrillar structures and leads to cell death by incompletely understood mechanisms. Work in multiple biological model systems, from simple baker's yeast to transgenic mouse lines, as well as in vitro studies, has illuminated molecular and cellular modifiers of prion disease. In this review, we focus on intersections between PrP and the proteostasis network, including unfolded protein stress response pathways and roles played by the powerful regulators of protein folding known as protein chaperones. We close with analysis of promising therapeutic avenues for treatment enabled by these studies.
- 25 November 2020
- Published by The Royal Society in Open Biology
- Vol. 10 (11) , 200282
Open AccessUnderstanding and exploiting interactions between cellular proteostasis pathways and infectious prion proteins for therapeutic benefit
Several neurodegenerative diseases of humans and animals are caused by the misfolded prion protein (PrP Sc ), a self-propagating protein infectious agent that aggregates into oligomeric, fibrillar structures and leads to cell death by incompletely understood mechanisms. Work in multiple biological model systems, from simple baker's yeast to transgenic mouse lines, as well as in vitro studies, has illuminated molecular and cellular modifiers of prion disease. In this review, we focus on intersections between PrP and the proteostasis network, including unfolded protein stress response pathways and roles played by the powerful regulators of protein folding known as protein chaperones. We close with analysis of promising therapeutic avenues for treatment enabled by these studies.